Previous Close | 12.81 |
Open | 13.00 |
Bid | 13.25 x 3000 |
Ask | 14.74 x 4000 |
Day's Range | 12.81 - 13.37 |
52 Week Range | 8.37 - 19.34 |
Volume | |
Avg. Volume | 2,111,930 |
Market Cap | 1.565B |
Beta (5Y Monthly) | 1.52 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.13 |
Earnings Date | Nov 07, 2022 - Nov 11, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 24.08 |
Subscribe to Yahoo Finance Plus to view Fair Value for ISEE
Biopharmaceutical companies have been struggling since 2021 and that narrative isn’t immediately changing. However, not every firm deserves this fate. In fact, investors can find great opportunities with “cheap” biotech stocks to buy now. There are many reasons for investor pessimism that could soon ease. For instance, drug innovation has stagnated in 2022. Companies also haven’t been able to announce as many positive clinical readouts to build confidence. These both could change in a jiffy if a
PARSIPPANY, N.J., August 03, 2022--Iveric Bio announced the Company will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022.
PARSIPPANY, N.J., August 02, 2022--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.